DJIA 17,475.83 35.24 0.20%
NASDAQ 5,037.14 -2.63 -0.05%
S&P 500 2,071.91 4.27 0.21%
market minute promo

Delcath Systems, Inc. (NASDAQ: DCTH)



company name or ticker

Delcath Receives Orphan Drug Designation From FDA For Melphalan To Treat Cholangiocarcinoma

Worst Performing Industries For June 2, 2015

Delcath Systems (DCTH) Weak On High Volume

Health Care Sector Update for 05/29/2015: DCTH,KBIO,SVON,XXII

Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015

Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Ye

Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years

ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open F

ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open For Enrollment

Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic

Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma

3 Basic Checks To Value Cheap Net Net Stocks

Delcath Adds New U.S. Center To Global Phase 2 Hepatocellular Carcinoma Program

See More Articles...